Nanobody CAR t-cells take on hard-to-treat leukemia in new trial
NCT ID NCT06880913
First seen Mar 31, 2026 · Last updated May 05, 2026 · Updated 8 times
Summary
This study tests a new type of CAR T-cell therapy that uses tiny antibodies (nanobodies) to target two proteins, CD19 and CD22, on leukemia cells. It is for people aged 12 to 65 whose B-cell acute lymphoblastic leukemia has come back or stopped responding to other treatments. The goal is to see if this therapy is safe and can put the leukemia into remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Deparment of Hematology, Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.